Author

L. A. Shehadeh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pharmacology & Toxicology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Kamiar· 1 shared A. Kuczmog· 1 shared C. I. Irion· 1 shared D. Szczesna-Cordary· 1 shared E. C. Martinez· 1 shared E. S. Buys· 1 shared F. Jakab· 1 shared G. D. Lopaschuk· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Kamiar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Sarcomeric SRX:DRX Equilibrium in Alport and LDLR/P407 Mouse Models of HFpEF.

A. Kamiar, M. M. Williams, J. M. C. Capcha, K. Kazmierczak, J. Liang, G. D. Lopaschuk, K. A. Webster, D. Szczesna-Cordary, L. A. Shehadeh

The paper quantifies SRX and DRX myosin states in HFpEF mouse models, finding altered SRX:DRX proportions linked to specific cardiac phenotypes.

bioRxiv · Feb 20, 2024 · PreprintCell Biology

Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19

S.-T. Chuang, H. Papp, A. Kuczmog, R. Eells, J. M. Condor Capcha, L. A. Shehadeh, F. Jakab, P. Buchwald

This paper shows methylene blue inhibits SARS-CoV-2 spike-ACE2 interactions and viral replication, with potential as an antiviral for COVID-19.

bioRxiv · Mar 22, 2022Pharmacology & Toxicology

Soluble guanylate cyclase stimulation mitigates skeletal and cardiac muscle dysfunction in a mdx model of Duchenne muscular dystrophy

L. Zhang, Y. Xu, K. Yousefi, C. I. Irion, R. A. Alvarez, S. M. Krishnan, J.-P. Stasch, E. C. Martinez, E. S. Buys, P. Sandner, L. A. Shehadeh, J. M. Percival

This study shows that stimulating soluble guanylate cyclase (sGC) with BAY41-8543 reduces skeletal and cardiac muscle dysfunction in mdx mice, suggesting sGC as a therapeutic target for Duchenne muscular dystrophy.

bioRxiv · Feb 14, 2021 · PreprintPhysiology